Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

Rhea-AI Summary

Pulnovo Medical has appointed Dr. Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership.

As former Chief Medical Officer at Edwards Lifesciences (NYSE: EW), Dr. Duhay was instrumental in developing the TAVR program, which generates over $4.0 billion in annual revenue across 80+ countries. His experience includes leading 88 clinical studies and working with key regulatory bodies like FDA and CMS.

This appointment strengthens Pulnovo's global medical leadership as it advances its Pulmonary Artery Denervation (PADN) program and expands internationally.

Positive

• Appointment of highly experienced former Edwards Lifesciences CMO with 25+ years of expertise
• Dr. Duhay's proven track record in developing TAVR, a $4.0B revenue program
• Experience leading 88 clinical studies and working with major regulatory bodies
• Strategic strengthening of medical leadership for PADN program advancement

Negative

• None.

SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer.

Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE: EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR)—a transformative therapy now recognized as one of the most successful cardiovascular procedures in the history of medical devices., with over $4.0 billion in annual revenue and adoption in more than 80 countries.

His career spans leadership of 88 clinical studies across multiple specialties and close collaboration with global regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS).

With Dr. Duhay's appointment, Pulnovo strengthens its global medical leadership as it advances its Pulmonary Artery Denervation (PADN) program and expands its footprint in international markets. His proven track record in bringing paradigm-shifting cardiovascular technologies from concept to global standard of care positions Pulnovo for its next phase of innovation and growth.

View original content:https://www.prnewswire.com/news-releases/pulnovo-medical-names-dr-francis-duhay-as-global-chief-medical-officer-302537529.html

SOURCE Pulnovo Medical

FAQ

Who is Dr. Francis Duhay and what is his new role at Pulnovo Medical?

Dr. Francis Duhay is a board-certified General and Cardiothoracic Surgeon with 25+ years of experience who has been appointed as Global Chief Medical Officer at Pulnovo Medical. He previously served as CMO at Edwards Lifesciences.

What was Dr. Duhay's major achievement at Edwards Lifesciences (NYSE: EW)?

At Edwards Lifesciences, Dr. Duhay played a crucial role in developing the Transcatheter Aortic Valve Replacement (TAVR) program, which now generates over $4.0 billion in annual revenue and is used in more than 80 countries.

How many clinical studies has Dr. Francis Duhay led in his career?

Dr. Duhay has led 88 clinical studies across multiple specialties and worked closely with global regulatory bodies including the FDA and CMS.

What is Pulnovo Medical's key program that Dr. Duhay will oversee?

Dr. Duhay will oversee Pulnovo Medical's Pulmonary Artery Denervation (PADN) program as the company expands its international footprint.